AbbVie announces positive pivotal phase III data for Elagolix
AbbVie, a global biopharmaceutical company in cooperation with Neurocrine Biosciences, has announced detailed results from two replicate pivotal phase III clinical trials evaluating the efficacy and safety of Elagolix in premenopausal women who suffer from endometriosis.
The data demonstrate that, compared to placebo at month three and month six, patients treated with Elagolix reported statistically significant reductions in scores for menstrual pain (dysmenorrhea, DYS) and non-menstrual pelvic pain (NMPP) associated with endometriosis as measured by the Daily Assessment of Endometriosis Pain scale.
"Endometriosis is often characterized by chronic pelvic pain, and can have a significant impact on patient function and quality of life," said Hugh S. Taylor, M.D., study investigator and Chair of the Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine. "The results presented today are encouraging for patients and demonstrate that Elagolix has the potential to be an important treatment option for women suffering from pain related to endometriosis."
In the two studies, both doses of Elagolix administered orally demonstrated a statistically significant (p ≤ 0.001) improvement versus placebo in the percentage of DYS and NMPP responders. In the first study, at month three, 46% of patients treated with 150 mg once daily and 76% of patients treated with 200 mg twice daily of Elagolix were classified as DYS responders, versus 20% of patients in the placebo group. Fifty% of patients treated with 150 mg once daily and 55% of patients treated with 200 mg twice daily of Elagolix were classified as NMPP responders, versus 36% of patients in the placebo group. The second pivotal phase III study demonstrated similar results.
"These results from the largest clinical trials ever conducted in endometriosis support AbbVie's continued efforts to pursue regulatory filing of Elagolix as a potential new treatment option for the disease's most prevalent symptoms," said Rob Scott, M.D., vice president, Development and Chief Medical Officer, AbbVie. "There have been few recent scientific advancements for patients suffering from endometriosis and physicians are in need of additional treatment options to help manage this chronic and painful disease."
At ASRM, AbbVie will present multiple abstracts highlighting primary and secondary efficacy and safety endpoint data from the phase III studies as well as research on the economic burden of endometriosis and endometriosis-related surgery in women in the United States. AbbVie plans to submit a New Drug Application to the U.S. Food and Drug Administration (FDA) for endometriosis in 2017.
The safety profile of Elagolix was consistent across both phase III trials and also consistent with prior Elagolix studies. In the first study, the most frequently reported adverse events (AEs) assessed over six months were hot flush (7%, 24%, 42% for placebo, 150 mg once daily and 200 mg twice daily, respectively), headache (10%, 15%, 17% for placebo, 150 mg once daily and 200 mg twice daily, respectively), and nausea (14%, 10%, 16% for placebo, 150 mg once daily and 200 mg twice daily, respectively). As anticipated by its mechanism of action, some AEs, such as hot flush were dose-dependent. The majority of hot flushes (>50%) were mild in severity. Discontinuations due to AEs were 5.9% and 6.1% for placebo in study 1 and study 2, respectively, 6.4% and 4.4% for 150 mg once daily in study 1 and study 2, respectively and 9% and 10% for 200 mg twice daily in study 1 and study 2, respectively.
The first pivotal phase III trial (M12-665) was a 24-week, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of Elagolix in 872 women, age 18 to 49, with moderate-to-severe endometriosis-associated pain. It was conducted at 175 sites in the U.S., Puerto Rico and Canada. An extension study (M12-667) permitted some women to be treated for an additional six months with these doses.
The second pivotal phase III trial (M12-671) employed the same design as the first pivotal phase III trial, was multinational, and included 815 women with moderate-to-severe endometriosis-associated pain across 226 sites in 13 countries (U.S. and 12 ex-U.S. countries). There was equal representation of enrollment from U.S. and Ex-U.S. countries. An extension study (M12-821) permitted some women to be treated for an additional 6 months with these doses. Together, these two phase III pivotal studies evaluated the safety and efficacy of Elagolix in nearly 1,700 women with moderate-to-severe endometriosis associated pain, representing the largest prospective randomized endometriosis trials conducted to date.